← Back to Clinical Trials
Recruiting Phase 2 NCT05422612

NCT05422612 Department of Defense PTSD Adaptive Platform Trial - Master Protocol

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05422612
Status Recruiting
Phase Phase 2
Sponsor Global Coalition for Adaptive Research
Condition Post Traumatic Stress Disorder
Study Type INTERVENTIONAL
Enrollment 800 participants
Start Date 2023-11-02
Primary Completion 2026-03

Trial Parameters

Condition Post Traumatic Stress Disorder
Sponsor Global Coalition for Adaptive Research
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 800
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2023-11-02
Completion 2026-03
Interventions
Intervention A Fluoxetine Hydrochloride (HCl)Intervention A PlaceboIntervention B Vilazodone Hydrochloride (HCl)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Participants are randomized among the multiple cohorts in the study and the resulting randomization enables sharing/pooling of control participants, where all interventions may be compared to a common control (placebo). This master protocol describes the default procedures and analyses for all cohorts; treatment-specific procedures will be described in the Master Protocol cohort-specific appendices. Individual cohorts may have additional eligibility requirements, safety and efficacy procedures, or endpoints, which will be described in corresponding intervention-specific clinicaltrials.gov records.

Eligibility Criteria

Inclusion Criteria: A participant must meet all the following criteria to be eligible to participate in this study: 1. Is willing and able to provide written informed consent. 2. ≥18 and \<65 years of age at Screening. 3. Meets Diagnostic and Statistical Manual for Mental Disorders, 5th edition (DSM-5) criteria for PTSD according to CAPS-5-R, Past Month assessment at Screening and Baseline. 4. The index trauma must have occurred more than 3 months prior to screening. 5. Has a CAPS-5-R, Past Month total score of ≥26 at Screening and Baseline. Note: The CAPS-5 scoring grid will be used to score answers and to calculate the total score to determine eligibility. 6. Is currently serving, or has previously served, in a branch of the US military service (ie, Air Force, Army, Navy, Marine Corps, and Coast Guard including Reserves and National Guard). 7. Agrees to consistently use an acceptable method of birth control as defined in Section 7.4.2 (required for both males and females who are of r

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology